Working with industry

The Leicester Precision Medicine Institute (LPMI) has many industrial partners and works with them to transform ideas into new products for the benefit of patients.

The LPMI has a strong track record of working collaboratively with industry at both the early stage of research and at the later stages of product development. We collaborate with small, medium, large and global enterprises in the areas of pharmaceuticals, biotechnology, medical technology, and diagnostics.

The LPMI also offers contract research and consultancy services.

The LPMI supports businesses developing innovative precision medicine solutions to enable and advance their adoption through:

  • Translational science from target through validation and to proof of concept;
  • Access to clinical samples and clinical infrastructure necessary to evaluate and demonstrate efficacy;
  • Access to specialists in AI, data analytics and large patient cohorts data training sets;
  • Access to new biological discoveries, molecular pathways and biomarkers;
  • Specialist services that your company may require such as data analytics and molecular analytics.

Working with Industry Examples

Breathomics- EMBER

The East Midlands Breathomics Pathology Node (EMBER) is a Medical Research Council (MRC) & Engineering and Physical Sciences Research Council (EPSRC) funded Molecular Pathology Node hosted at the University of Leicester partnering with University Hospitals of Leicester NHS Trust, Loughborough University and Industry.

EMBER is developing novel breath-based systems for molecular pathology. Exhaled breath contains volatile organic compounds (VOCs) that reflect biological processes occurring within the lung and, via the bloodstream more distant organs.  Projects include characterising patients with asthma, COPD and cardiovascular diseases.

The validation of a novel biomarkers for therapeutic interventions in colorectal cancer

PIs: Professor Karen Brown and Dr Sam Khan

Problem: Over a quarter of patients with colorectal cancer (CRC) present with metastatic disease for which the 5 year survival is just 8%. More effective agents are required to treat patients with metastatic disease, as well as novel prevention strategies to inhibit the development and progression of CRC. Treatment with curcumin shows promise as both a preventive and a therapy for colorectal cancer. The identification of biomarkers predicting sensitivity to curcumin would allow identification of a cohort of patients who are most likely to benefit from treatment.

Solution: To develop robust diagnostic/prognostic biomarkers for the anticancer activity of curcumin in colorectal cancer in patients. Stratification methods include using micro-satellite instability and tumour subtypes. The capability of the biomarkers to identify patient that positively respond to curcumin treatment will be validated in explanted tumour samples.  Patient benefit: Novel diagnostic/prognostic biomarkers will enable the stratification of patients with high-risk polyps in CRC to identify those individual who will gain the most benefit from curcumin treatment. This will open up the possibility of large stratified medicine programmes to assess the potential impact of curcumin on high risk polyps, development of CRC and CRC treatment.

Back to LPMI homepage

Share this page:


For LPMI Enquiries:

Professor Jacqui Shaw

Dr Ruth Barber

Dr Carl Edwards


t: +44 (0)116 223 1594


LD3 logo

LD3 Office:

+44 (0)116 252 3342